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Abstract
The human immunodeficiency virus (HIV) can be suppressed by highly active anti-retroviral therapy (HAART) in the majority
of infected patients. Nevertheless, treatment interruptions inevitably result in viral rebounds from persistent, latently
infected cells, necessitating lifelong treatment. Virological failure due to resistance development is a frequent event and the
major threat to treatment success. Currently, it is recommended to change treatment after the confirmation of virological
failure. However, at the moment virological failure is detected, drug resistant mutants already replicate in great numbers.
They infect numerous cells, many of which will turn into latently infected cells. This pool of cells represents an archive of
resistance, which has the potential of limiting future treatment options. The objective of this study was to design a
treatment strategy for treatment-naive patients that decreases the likelihood of early treatment failure and preserves future
treatment options. We propose to apply a single, pro-active treatment switch, following a period of treatment with an
induction regimen. The main goal of the induction regimen is to decrease the abundance of randomly generated mutants
that confer resistance to the maintenance regimen, thereby increasing subsequent treatment success. Treatment is switched
before the overgrowth and archiving of mutant strains that carry resistance against the induction regimen and would limit its
future re-use. In silico modelling shows that an optimal trade-off is achieved by switching treatment at &80 days after the
initiation of antiviral therapy. Evaluation of the proposed treatment strategy demonstrated significant improvements in
terms of resistance archiving and virological response, as compared to conventional HAART. While continuous pro-active
treatment alternation improved the clinical outcome in a randomized trial, our results indicate that a similar improvement
might also be reached after a single pro-active treatment switch. The clinical validity of this finding, however, remains to be
shown by a corresponding trial.
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Introduction
In 1996, the tremendous clinical success of highly active
antiretroviral therapy had led many researchers to believe that the
eradication of HIV would be feasible. However, it was soon
realized that inducible pro-virus persists in latently infected cells
despite ongoing therapy and that the latent reservoir prevents HIV
eradication within the patients lifetime [1]–[6].
Latent infection is established when CD4z T-lymphoblasts
containing integrated provirus [5,7] escape both immune effector
mechanisms and the cytopathic effects of the virus and revert to a
resting memory state [8]. Besides preventing eradication of HIV,
the latent reservoir also serves as a memory of any virus species
replicating during the course of HIV infection [9,10], including
drug resistant variants. The contents of this archive of resistance
are strong predictors of future treatment failure [9,11].
Despite the impressive improvement of antiviral therapy, many
patients still experience virological failure caused by the selection
of drug resistant virus populations. Current guidelines recommend
changing treatment after the confirmation of virological failure.
However, in the face of the rapid viral turnover this approach
could be sub-optimal [12]. Changing therapy after the appearance
of drug resistant mutants will (i) allow the resistant viral population
size to expand and evolve and (ii) lead to an archivation of resistant
viral strains. An optimal treatment strategy should therefore
prevent viral relapse with drug resistant strains and, more
importantly, prevent drug resistant mutants from establishing
latent infection.
Induction-maintenance (IM) approaches are used for the
treatment of a growing number of infectious- and neoplastic
diseases [13–15]. Typically, patients start with an intensified
induction regimen (composed of a number of potent and
potentially toxic drugs), which will subsequently be replaced by a
maintenance regimen (composed of a smaller number of less toxic
drugs) [16]. However, patients treated with a large number of
drugs are particularly vulnerable to drug interactions [17] and
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adverse side effects that complicate HIV therapy and seriously
undermine the success of clinical management [18].
Another approach to overcome the development of resistance is
to alternate antiretroviral therapy [19]. This strategy has been
shown to significantly delay virological failure [20,21], yet it is
flawed by its high psychological and physical burden [22].
We propose an approach that combines the advantages of
conventional IM- and treatment alternation strategies, but
minimizes their inherent disadvantages. We suggest a single,
pro-active treatment switch from an inducer drug combination to
a maintenance combination. The inducer drug combination
should rapidly lower the viral population size and eliminate
resistant mutants. Subsequently, it will be replaced by a
maintenance drug regimen with a completely different resistance
profile, before drug resistant strains are archived.
We have previously introduced a novel model of virus dynamics
and adaptation [23], which allows us to consider the distinct
molecular effects of all novel (and some developmental) HIV
drugs. In this article, we present a novel mathematical concept,
which prevents the emergence of drug resistance in each
individual realization (virtual patient) of the model by switching
between therapies. Utilizing this concept, we deduce a distribution
of (individual) switching-times, which we use to determine a single
fixed duration for the induction therapy, which increases the
treatment success probability in the whole virtual patient
population and which minimizes the risk for resistance to become
archived in the latent reservoir. Finally, the performance of this
novel induction-maintenance-strategy is evaluated against con-
ventional HAART therapy.
Results
Virus dynamics model
We have extended the existing viral dynamics model, described
in [23], for the compartment of very long lived, latently infected T-
cells TL (Fig. 1 and Materials and Methods section), which are
believed to prevent eradication of HIV [24] and to lead to the
archiving of drug resistance [9,10].
Briefly, the virus dynamics model (Fig. 1) comprises T-cells,
macrophages, free non-infectious virus (TU,MU,VNI, respectively),
free infectious virus of mutant strain i,VI(i), and five types of
infected cells belonging to mutant strain i: infected T-cells and
macrophages prior to proviral genomic integration (T1(i) and
M1(i), respectively) and infected T-cells and macrophages after
proviral genomic integration (T2(i),TL(i) and M2(i), respectively).
The latently infected cell type TL does not express viral genes, but
can become activated with rate a, transforming this cell into a
virus producing post-integration infected T-cell T2. The average
rates of change of the different species are displayed in the Materials
and Methods section. All parameter values have been chosen
Figure 1. Extended virus dynamics-, mutation- and drug interference model. Target cells (TU,MU) can become successfully infected by
infective virus VI with infection rate constants bT and bM, respectively, creating early infected cells T1 and M1 . Infection can also be unsuccessful
after the step of viral fusion (rate constant CLT and CLM), eliminating the virus and rendering the cell uninfected. Early infected cells T1 andM1 can
also destroy essential viral proteins or DNA prior to integration, returning the cell to an uninfected stage. The genomic viral DNA can become
integrated with rate constants kT and kM creating post-integration, infected cells T2,TL and M2 . The latently infected cell type TL does not express
viral genes, but can become activated with rate a, transforming this cell into a productively infected T-cell T2 . Virus producing cells T2,M2 release
new infectious- and non infectious virus VI and VNI with rate constants NT, cNT{NT  and NM, dNM{NM , respectively. Phenotypic mutation
occurs at the stage of viral genomic integration kT,kM (see [23]). All cellular compartments x can get destroyed by the immune system with
respective rate constants dx and the free virus (infectious and non-infectious) gets cleared with rate constant CL (not shown in the illustration). The
site of drug interference with the replicative cycle of HIV is indicated by blue bars for the respective drug classes (NRTIs, NNRTIs, FIs, CCR5-inhibitors,
INIs, PIs, and maturation inhibitors).
doi:10.1371/journal.pone.0018204.g001
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according to previous studies and are displayed in Table 1. Since
some viral strains are present only in very low copy numbers, we
used a hybrid stochastic-deterministic approach [25] to perform
simulations (see Materials and Methods section for details).
Treatment change before virological failure
Currently, changes of antiretroviral treatment regimes are
largely triggered by virological failure or toxicity. In Fig. 2A, we
show the simulated viral load in the case of first line treatment
failure. The corresponding population dynamics of HIV are
shown in Fig. 2B. During first line treatment failure, resistant
mutants (green- and cyan colored lines in Fig. 2B) are selected
from the quasi-species population and quickly evolve into the
dominant virus population, leading to viral rebound. While the
total virus population is temporarily shrinking, mutants that confer
resistance against a potential follow-up treatment (red line, dark
grey shaded area in Fig. 2B) are depleted (possibly eradicated).
However, during viral rebound the total viral population re-
expands and consequently erroneous reverse transcription gener-
ates novel mutants that can confer resistance against a second line
therapy. Once the viral population size has been restored, the
second line therapy, although composed of entirely different drugs,
is as likely to fail as before the initiation of first line therapy.
Furthermore, it is likely that drug resistant viral strains become
archived while they dominate the viral population (light grey
shaded area in Fig. 2B).
In Fig. 2C, we show the viral load dynamics during the
proposed induction-maintenance therapy. The corresponding
population dynamics of HIV are shown in Fig. 2D. The inducer
combination reduces the viral load (see Fig. 2C). However,
treatment is changed (vertical dashed black line) to the
maintenance combination, before resistant strains (green and cyan
line in Fig. 2D) can become more abundant than the wildtype
(magenta line in Fig. 2D). Therefore, at the time of treatment
change (vertical dashed black line in Fig. 2D), total virus has been
decreased and mutants that confer resistance to the maintenance
therapy (red line, dark grey shaded area in Fig. 2D) are likely to be
eradicated, which improves the probability to achieve durable
virological suppression with the maintenance therapy. With this
strategy, the abundance of the wildtype is larger than the
abundance of drug-resistant mutants, which lowers the probability
that drug resistance enters the latent reservoir (light grey shaded
area is absent in Fig. 2D).
In order to determine the optimal time point for switching from
inducer- to maintenance- drug combinations, tswitch, we first
determined relevant sets of parameters for (i) the in vivo efficacy
g(wt,j) of each utilized drug j against the wildtype wt and (ii) the in
vivo fitness loss that is associated with resistance development s(i)
(shown in Table S1), since the corresponding in vivo parameters are
known to vary substantially between different patients, e.g. [26]. For
simulation purposes, we assumed that a single point mutation is
sufficient to create high-level resistance (99%) to a single drug. This
is somewhat a worst-case assumption, but is justified for a number of
drugs, see e.g. [27,28]. Relevant clinical failure rates after one year
in previously treatment-naive patients, who receive HAART in a
clinical trial setting, are &15{25% [29], (see Table S1).
We then use an algorithm that automatically switches from
inducer- to maintenance drug combination, minimizing virological
failure for each realization (virtual patient), respectively. A
histogram of the derived (individual) switching times from a total
of 6000 simulations is shown in Fig. 3. Based on the histogram, we
finally chose a fixed time tswitch for changing from induction- to
maintenance therapy. In the sequel, we evaluate, if the chosen
time tswitch to change from inducer- to maintenance combination
leads to a general improvement compared to conventional
HAART therapy, in terms of treatment success and drug
resistance archiving.
Determination of treatment changing time
In [23] we introduced the ‘reproductive capacity’ Rcap(j). For
the extended model used herein, we have provided the derivation
of Rcap(j) in the Materials and Methods section. The reproductive
capacity Rcap(j) can be envisaged as the amount of offspring that
the whole viral population is expected to produce under some
treatment j during one round of replication. It can be calculated
from any model simulation and enables to evaluate each state of
the infection from the perspective of any potential treatment j. As
the viral population adapts to some currently applied treatment,
Rcap(j) changes accordingly: Rcap(j) is large initially and decreases
subsequently until drug resistant strains develop and render the
treatment j inefficient. We want to assess the point in time, when
some inducer- drug combination stops to provide any benefits (in
terms of the viral population) for the next drug combination
(maintenance combination). We therefore evaluate Rcap(j) for
j~maintenance combination while the induction combination is
applied and change from the induction- to the maintenance
therapy when Rcap(j) reaches its minimum;
switch if :
d
dt
Rcap(j)~0: ð1Þ
The derived switch-times are displayed in Fig. 3. We chose the
0.5th percentile at tswitch~80 days as a fixed time for treatment
change in the forthcoming evaluation of the proposed induction-
maintenance-strategy.
Implementation of conventional vs. proposed induction-
maintenance-strategy
In order to reflect the clinical practice of HIV care, we have
implemented the following routine for assessing the efficacy of the
applied treatment combinations.
Table 1. Model parameters generally used in simulations.
Param. Value Ref. Param. Value Ref.
lT 2:109 [64] lM 6:9:107 [65]
dT,dT1 0.02 [65] dM,dM1 0.0069 [65]
dT2 1 [36] dM2 0.09 [23]
CL 23 [36] dL 10{4 [16,66]
dPIC,T 0.35 [67,68] dPIC,M 0.0035 [23]
a 10{3 [66] p 8:10{6 [66]
m 2:2:10{5 [42] rrev 0.33 [68,69]
kT(wt,w) 0.35 [68] kM(wt,w) 0.07 [23]
bT(wt,w) 8:10
{12 [49] bM(wt,w) 10
{14 [23]
bNT 1000 [65] bNM 100 [65]
b:q:rPR 0.67 [23] - - -
All parameters refer to the wildtype 0wt’ in the absence of drug treatment w. All
parameters in units [1/day], except p, rrev , b
:q:rPR (unit less) and m in
½1=(rev:trans::base). CLT=M(wt,w)~ 1
rrev
{1
 
:bT=M(wt,w),
NT=M(wt,w)~b
:q:rPR
:bNT=M [23].
doi:10.1371/journal.pone.0018204.t001
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Our virtual patients are monitored every month for efficacy
assessment until virus levels fall below the limit of detection (50 HIV
RNA/mL plasma). Thereafter, they are monitored every other
month. Virological failure has been defined according to treatment
guidelines [24]: At the first efficacy assessment (one month after
treatment initiation), viral load should have fallen by at least 2 logs
[HIV RNA/mL plasma]. Each consecutive measurement should be
below the previous assessment. By month 4, viral load should be
below the level of detection (50 HIV RNA/mL plasma). After that,
detectable virus is defined as virological failure.
We implemented conventional HAART in the following way:
The virtual patients are initially treated with a drug combination
consisting of two nucleoside reverse transcriptase inhibitors
(NRTIs) and one non-nucleoside reverse transcriptase inhibitor
(NNRTI) (e.g. tenofovir (TDF) + emtricitabine (FTC) + efavirenz
(EFV)), until virological failure is detected, in which case treatment
is changed to a second line regimen consisting of a protease
inhibitor (PI), an integrase inhibitor (InI) and an entry inhibitor
(EI) (e.g. ritonavir (RTV) -boosted PI + raltegravir (RLV) +
maraviroc (MVR)).
In the proposed induction-maintenance-strategy, patients are
initially treated with a combination consisting of a PI, an InI and
an EI, until tswitch~80 days. After that, a treatment consisting of
two NRTIs and one NNRTI is applied. If failure is detected at any
efficacy assessment time point, treatment change is applied.
In the following, we performed 1000 hybrid stochastic-determin-
istic simulations for each relevant parameter set (deduced from Table
S1) and counted the number of realizations, in which virological
failure occurred. Furthermore, we assessed, if the number of drug
resistant mutants in the very long-lived infected cells TL was higher
at the end of the simulation than upon initiation of treatment. In this
case we recorded ‘‘archiving’’ of drug resistance. The results of our
simulations are discussed in the next section.
Proposed induction-maintenance-strategy improves
success rate and minimizes archiving of drug-resistance
Fig. 4A shows that the proposed induction-maintenance-
strategy (blue line) with a fixed treatment switch time of
tswitch~80 days leads to a significant reduction in the probability
to experience virological failure compared to the conventional
treatment strategy (red line). This observation holds true for a wide
range of parameters (see Table 2, second column). In only two
cases, where failure rarely occurs during conventional therapy, we
do not get significant differences at the p = 0.05 level.
Fig. 4B shows that virological failure and the average number of
archived drug resistance mutations are strongly correlated (spearman’s
correlation coefficient rSw0:99, pv0:001). This indicates that vi-
rological failure is a strong predictor for drug resistance archiving.
Tables 2 (third–fifth column) show the number of cases in which
archiving of multi-drug resistant viral strains (with §2, §3 and
Figure 2. Abundance of viral mutants during first-line treatment failure and during proposed induction-maintenance strategy.
A: Plasma virus load during first line treatment failure (blue line). B: Total abundance of distinct viral mutants during first-line treatment failure.
C: Plasma virus load (blue line) during proposed induction-maintenance strategy with switch between induction- and maintenance treatment at 80
days (vertical dashed line). D: Total abundance of distinct viral mutants during proposed induction-maintenance strategy. The magenta line denotes
the abundance of wildtype virus. Green- and cyan lines denote the abundance of mutants that are part-resistant against the first line regimen
(resistant against two out of three drugs) and mutants that are fully resistant against the first line regimen, respectively. The red lines denote the
abundance of all mutants, which are part-resistant against a second line treatment. The area under the red line is highlighted by the dark grey shaded
area, to stress the negative impact of these mutants on the success of a second line regimen. The light shaded area in panel B indicates that resistant
mutants are more abundant than the wildtype and therefore highlights when drug resistance archiving in latently infected cells takes place. The
simulations were performed by assuming 70% drug efficacy g(wt,j) and a fitness loss s of 20% per drug resistance mutation. Furthermore, it was
assumed that a single point mutation can confer absolute resistance to a single drug.
doi:10.1371/journal.pone.0018204.g002
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§5 drug resistance mutations) occurred in the latent reservoir,
under the proposed induction-maintenance strategy and conven-
tional HAART, respectively. It can be seen that the proposed
treatment strategy leads to a significant reduction in multi-drug
resistance archiving for the majority of parameters evaluated. This
indicates, that although two treatment lines have been used for the
novel therapy, more therapeutic options are on average available
in the follow-up period, compared to conventional therapy.
Discussion
We have presented and tested (in terms of a mathematical
model) a very simple treatment strategy that can lead to significant
reductions in virological failure in comparison to conventional
HAART treatment. A unique drug combination (inducer
combination) is used for a short time (80 days) and pro-actively
switched to a maintenance combination. The purpose of the
inducer combination is to decrease viral population size and
thereby increase the likelihood that the subsequent therapy
(maintenance) will achieve durable suppression. Clinical imple-
mentation of this novel treatment strategy requires only one
additional clinical visit at 80 days in comparison with the
conventional HAART therapy. The important finding of our
study is, that although two drug combinations are always utilized
during the proposed induction-maintenance strategy, less archiv-
ing of drug resistance occurs in comparison with a conventional
treatment strategy, where a second treatment line would be
applied only in the case of virological failure or toxicity. Less drug
resistance archiving implies that more treatment options will be
available for the follow-up and long-term management of HIV-
infected patients when the proposed induction-maintenance
treatment strategy is used (see Table 2, third–fifth column).
Fig. S1 shows that only a few archiving events (§40 fully
resistant mutants) are sufficient to eliminate treatment options
permanently. The number of circulating latently infected cells is
small [2,7,30,31]. Detecting a small subset of mutants within the
circulating latently infected cells is experimentally not feasible,
because standard sequencing technology will detect the major
strains [32], while novel, second generation methods require large
samples [33]. Hence, mathematical modelling is a reasonable tool
to investigate drug resistance archiving following treatment
application.
The time for switching between combinations tswitch ( = 80 days)
is the most critical parameter for the success of the proposed
strategy. The following two considerations have to be taken into
account: (i) The inducer combination should be applied only for a
Figure 3. Histogram of optimal, individual treatment switching
times. Switching times for changing from inducer- to maintenance
therapy were automatically determined and carried out (using eq. (1)).
The 0.5th percentile, marked by the red line, was determined and the
corresponding time tswitch~80 days was used as a fixed value in the
suggested strategy to switch from inducer- to maintenance therapy.
Hybrid deterministic-stochastic simulations were performed at clinically
relevant parameter sets (see Table S1). Drug switches occurred in a total
of 5478 out of 6000 simulations.
doi:10.1371/journal.pone.0018204.g003
Figure 4. Kaplan-Meier estimates for treatment success, and correlation between virological failure and archiving of drug
resistance. The plots summarize the results trough the whole simulated parameter space from Table 2 (12000 simulations in total). A: Probability of
no virological failure (%) for the IM-strategy (blue line) and the conventional therapy (red line), respectively. Dashed lines are the 95% confidence
ranges, calculated using Greenwood’s formula. Virological failure was defined according to [24] and is summarized in section ‘‘Implementation of
conventional vs. proposed induction-maintenance-strategy’’. B: The probability to virological failure vs. the average number of drug resistance
archiving in the latent reservoir. A strong positive correlation (pv0:001) between virological failure and drug resistance archiving exists, as indicated
by spearman’s non-parametric rank correlation coefficient rSw0:99.
doi:10.1371/journal.pone.0018204.g004
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short time, to prevent the selection and archiving of mutants,
which are resistant to the current drug combination and would limit
the further use of this drug combination (risk of the strategy), (ii)
while at the same time, it has to be applied long enough to possibly
eradicate viral mutants, which are resistant to the next drug
combination (the benefit of the strategy).
The time required for resistant mutants to emerge, depends on
their abundance before the initiation of therapy (if they pre-exist
and are selected from the population) and also on their genetic
distance to the wildtype (if resistance is de novo developed). As
discussed above, we determine the abundance of mutants at the
time of therapy initiation by utilizing the deterministic fix-point as
starting condition for our simulations. We have shown the non-
inferiority of our approach in Fig. 5, if drug resistant mutants are
more abundant than expected. We have assumed the shortest
genetic distance possible between wildtype and fully drug resistant
mutants (one mutation is sufficient to create full resistance against
a single drug, three distinct mutations are required for full
resistance against a triple-drug combination). For some drugs,
however, subsequent accumulation of mutations creates fully drug
resistant mutants [34]. In our model, drug resistance might
therefore develop more rapidly than in vivo for drugs with a large
genetic barrier [35]. This implies that in vivo the inducer
combination could possibly be applied for a longer time frame
than the 80 days utilized in our model, if the genetic distance
between wildtype and fully drug resistant mutant was greater than
considered here (greater than one point mutation). However, our
results demonstrate that even a very short time (80 days) in which
the inducer combination is applied, can improve the clinical
outcome significantly (see Fig. 4 and Table 2). This short time
already minimizes the probability that drug resistance emerges
and can, in that sense, be considered safer than a longer induction
phase.
Eradication of viral mutants depends critically on their
abundance prior to the initiation of therapy and on the rate at
which viral compartments (and therefore resistant mutants) are
cleared in vivo. The elimination of viral compartments in vivo has
been quantified and validated in a number of clinical studies [36–
38]. We used the expected abundance of viral mutants (the
deterministic fix-point of the model) to estimate the abundance of
different viral mutants at the time of treatment initiation. In Fig. 5
we show non-inferiority of our approach in the case, where an
unexpectedly high abundance of drug resistant mutants is present
(1% of the wildtype; detection limit of second generation
sequencing technologies [33,39,40]), which would require longer
time for eradication.
One limitation of the proposed induction-maintenance strategy
is the potential inability to eliminate viral strains, that carry
resistance to the maintenance therapy. This is particularly the
case, if viral mutants, which carry resistance against all (or at least
the majority of) drugs in the maintenance combination, are
archived in the latent reservoir prior to treatment initiation. In Fig.
S1B, we have quantified that § 40 fully resistant viral mutants in
the latent reservoir eliminate treatment options permanently.
However, the likelihood for fully resistant archival copies (resistant
against all drugs in the maintenance regimen) in the treatment
naive patient, who was infected with wildtype 0wt’ virus, is
relatively small. Based on quasi-species theory, Ribero et al. [41]
calculated the pre-treatment frequency of viral mutants. According
to [41], the frequency of double mutants (part-resistant) relative to
the wildtype equals
Fdbl::wt~
m2
sdbl:
: 1
s1
z
1
s2
{1
 
, ð2Þ
where s1,s2 and sdbl: are the selective disadvantages of the strain
Table 2. Probability of virological failure and -archivation of multi-drug resistant virus during suggested induction-maintenance-
(IM) vs. conventional HAART strategy.
Parameter set Failure rate Probability of multi-drug resistance archivation
ID (1{g; s) IM, HAART $2 mutations $3 mutations $5 mutations
R1 (0:7; 0:3) 1.7, 4.8% 1.8,4.8% 1.7,4.8% 0,0.1%
R2 (0:7; 0:25) 4.2, 14.2% 4.8,14.2% 4.2,13.9% 0.1,0.2%
R3 (0:7; 0:2) 6.6, 41.8% 18.5,42.2% 9.6,41.6% 0.1,2.9%
R4 (0:75; 0:25) 0.9, 2.8% 0.9,2.9% 0.9,2.8% 0,0%
R5 (0:75; 0:2) 1.8, 12.5% 2.2,12.6% 1.8,12.5% 0,0.4%
R6 (0:8; 0:2) 0.7, 2.2% 0.8,2.3% 0.7,2.2% 0,0.2%
R7 (0:8; 0:15) 3.1, 21.9%  2.8,22.1%  3.1,21.9%  0.2,0.9% 
R8 (0:8; 0:1) 7.9, 44%  9.3,44%  8.3,44%  0.7,14.6% 
R9 (0:85; 0:15) 0.6, 0.6% 0.9,1.3% 0.6,0.6% 0,0%
R10 (0:85; 0:1) 2.4,7.1%  2.7,8.1%  2.4,7.2%  0.3,0.4%
R11 (0:85; 0:05) 33.7, 59.1%  34.7,59.5%  34,59.3%  3.4,17.2% 
R12 (0:9; 0:05) 1.2, 1.8% 2.3,2.5% 1.3,1.8% 0.1,0.1%
Columns 2–5 show the distinct treatment outcome for the suggested induction-maintenance strategy (left entry) and a conventional HAART strategy (right entry) for
different parameter sets R1–R12 in terms of mutation-associated reproductive fitness losses s and different levels of drug efficacy (1{g) (indicated in column 1),
following 1000 simulations respectively. Relevant parameter combinations had been identified beforehand, see Table S1 and section ‘‘Treatment change before
virological failure’’. Column 2: Percentage of virological failure after 2 years of therapy according to the HIV treatment guidelines (summarized in section
‘‘Implementation of conventional vs. suggested induction-maintenance strategy’’). Column 3–5: Probability of multi-drug resistance archiving during the proposed
strategy and during conventional HAART strategy. Cross tab x2 tests of independence between treatment strategy (suggested vs. conventional strategy) and outcome
(virological failure or archivation of multi-drug resistance) are stated. A small p-value indicates that the distinct outcome depends on the treatment strategy and is not
due to random effects (** pv0:001, * pv0:05).
doi:10.1371/journal.pone.0018204.t002
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carrying the first-, the second- and the both drug-resistance
mutations and m~2:16:10{5 is the single point mutation rate [42].
It is reasonable to assume that resistant mutants are, at best, as
likely to enter the latent reservoir as the wildtype in the absence of
any drugs, due to their inherent fitness loss, i.e. P(dbl:jTL)
ƒFdbl::wt. Considering a maintenance combination consisting of
efavirenz (EFV), tenofovir (TDF) and emtricitabine (FTC), with
primary resistance mutations K103N, K65R and M184V and
respective selective disadvantages for the single-point mutants
sK103N~0:125,sK65R§0:8 and sM184V§0:9 [43] and additive
fitness losses in the double mutants sK103N=K65R,sK103N=M184V,
sK65R=M184V (i.e. sdbl:~1{(1{s1):(1{s2)), the probability that
mutants, resistant against two out of three maintenance drugs,
enter the latent reservoir are P(K103N=K65RjTL)ƒ5:10{9,
P(K103N=M184VjTL)ƒ4:10{9 and P(K65R=M184VjTL)ƒ
6:5:10{10 respectively. Using in vivo data, Chun et al. [7]
estimated the average number of latently infected cells with
replication-competent provirus to be TL&1:4:106 cells, so that
the expected number of partly-resistant mutants E(dbl:,TL)~
TL:P(dbl:jTL) that are archived prior to treatment initiation
is E(K103N=K65R,TL)ƒ0:007,E(K103N=M184V,TL)ƒ0:006
and E(K65R=M184V,TL)ƒ0:0009. In other words, it is very
unlikely that part-resistant mutants are archived in patients prior
to treatment, since E(dbl:,TL)%1. Furthermore, part-resistant
mutants are still susceptible to one out of the three drugs in the
maintenance combination. For triple-drug (fully) resistant strains,
the likelihood of archival copies is even smaller.
Infection with drug resistant strains, mainly against established
drug classes, is a major, growing health concern [44]. During
infection with drug-resistant viral strains, archivation in the latent
reservoir is likely, since this reservoir is established early in the
infection [45]. If the circulating viral population reverses to a drug-
susceptible type, archived resistant mutants from the time of
infection might remain undetected and can complicate subsequent
treatment (see Fig. S1). This particular circumstance applies
equally to the proposed induction-maintenance therapy and
conventional HAART.
For our strategy, we have chosen drugs from novel classes (e.g.
InI, EI) for the inducer-combination, while we selected drugs from
well-established classes for the maintenance combination (NNRTI,
NRTI). This has the following rationale: The inducer combination
will only be applied for a short time (80 days), while the
maintenance combination could possibly be applied for much
longer periods of time (until it fails, or toxicological events occur).
Second or third generation drugs within the established drug-
classes are often more convenient to apply (e.g. once daily dosing)
and are less toxic, which has important implications for the long-
term management of HIV [46]. Secondly, drugs from the novel
drug classes (InI, EI), are currently not available as generic
formulations, whereas low-cost alternative drugs exist for estab-
lished drug classes. Therefore, in order to reduce treatment costs,
it is of advantage to select a strategy, in which inexpensive drugs
can be used for the majority of time, while cost-intensive ones are
only applied for short treatment periods.
Some drug classes can cause a distinct viral load decline. In
particular, the only approved InI raltegravir causes a more rapid
viral load decay, compared with other HIV inhibitors [47,48]. It
might therefore seem logical, based on viral load decay, to use
raltegravir in the induction treatment. It has been shown,
however, that the faster viral decay with raltegravir could be a
consequence of the particular site of action of InIs within the viral
life cycle and may not be due to an overall increased removal rate
of replication-competent viral compartments by raltegravir
[23,49]. Long-term studies of raltegravir- versus efavirenz-based
HAART showed equal outcomes with either therapies [50,51],
arguing against the superiority of raltegravir-based drug combi-
nations in removing replication-competent virus; however, further
analysis is required.
Intuitively, it might be more advantageous to use drug
resistance tests to guide treatment switches, instead of using a
fixed time for a pro-active switch from inducer- to maintenance
combination [19]. However, under the considerations discussed
above, a switch from inducer- to maintenance combination should
be applied before any resistant strains become abundant. This
implies that the most frequent viral strain at the time of switch
should be the wildtype. Standard assays fail to detect minority
species [32]. Ultra-deep/pyro-sequencing might provide a more
holistic picture of the quasi-species composition and can pick up
viral mutants that are abundant in &1% of the quasi-species
population and if the sample is large enough [33,39,40]. However,
even in this case, viral mutants are likely to dominate once the
results are available (w1 week), owing to the rapid viral kinetics
[52].
In our in silico study, we considered time-invariant, as well as
anatomically homogeneous average drug efficacy (1{g), for the
ease of modelling. It is also possible to consider drug- and patient-
specific time-varying pharmacokinetics and to study the impact of
compliance on drug resistance development. However, if compli-
ance is identical between the two study arms, the qualitative
difference between the outcome of conventional HAART versus
the proposed induction-maintenance strategy is not expected to
change. As shown in Table 2, the proposed induction-mainte-
nance therapy performs better than conventional HAART for a
wide range of parameter values for (1{g). Furthermore, it was
shown in a clinical study [20,21] that treatment alternation leads
to significantly less virological failure than conventional HAART,
when compliance is imperfect but identical between the two study
arms. However, since the study in [20,21] is not identical to the
Figure 5. Kaplan-Meier estimates of treatment success (prob-
ability of no virological failure) for very high initial abundance
of drug resistant mutants. The figure shows the outcome of 500
simulations for the proposed induction-maintenance strategy (blue
line) and for the conventional HAART therapy (red line), respectively.
Dashed lines indicate the 95% confidence ranges, calculated using
Greenwood’s formula. The initial abundance of drug resistant mutants
was set to 1% of the population. Other parameter values: (1{g)= 0.75,
s=0.8.
doi:10.1371/journal.pone.0018204.g005
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treatment strategy presented herein, a clinical study should be
performed to fully investigate the potential of the proposed
induction-maintenance strategy. Ideally, this prospective random-
ized trial could evaluate the time to virological failure in patients
taking a single unchanged regimen and patients on induction-
maintenance regimens. Importantly, the trial should be designed
to evaluate whether the induction maintenance strategy affects the
durability of second- and third line regimens. The presence and
relative frequency of viral minority populations as well as their
mutational patterns could be monitored by analyzing proviral
DNA from circulating T-cells using, e.g., next-generation
sequencing. This data could serve to validate our mathematical
model.
Based on a recent, successful pre-exposure prophylaxis (PrEP)
trial, where emtricitabine (FTC) + tenofovir (TDF) were given to
high-risk individuals [53], it could be envisioned that PrEP is used
more broadly. One risk with such a strategy is the selection of
FTC/TDF resistance, which occurred in both subjects with acute
HIV infection at enrolment in the PrEP trial [53]. Furthermore,
there is a high risk for the selection of drug resistance, if subjects
get infected despite PrEP (e.g. due to low adherence;v50% in the
PrEP trial [53]). While FTC/TDF is a core component of first-line
HAART, the long-term epidemiological consequences of drug-
resistance selection are of utmost importance. One interesting
question is whether the proposed induction-maintenance therapy
can re-sensitize those subjects towards FTC/TDF treatment, who
had become infected with HIV despite PrEP. While a thorough
analysis of this question is beyond the scope of the current article,
related scenarios are frequently encountered in the context of
prevention of mother-to-child transmission (MTCT) programs,
when short-course intrapartum nevirapine is used. In the MTCT
context, protease-inhibitor-based induction therapy has been used
for the re-sensitization of pre-exposed children towards nevirapine
[54]. Further analysis, however, is required to elucidate the
potential of induction-maintenance strategies for re-sensitization of
pre-exposed HIV infected individuals.
Materials and Methods
Model Equations
The virus dynamics model (Fig. 1) comprises T-cells, macro-
phages, free non-infectious virus (TU,MU,VNI, respectively), free
infectious virus of mutant strain i,VI(i), and five types of infected
cells belonging to mutant strain i: infected T-cells and macro-
phages prior to proviral genomic integration (T1(i) and M1(i),
respectively) and infected T-cells and macrophages after proviral
genomic integration (T2(i),TL(i) and M2(i), respectively). The
latently infected cell type TL does not express viral genes, but can
become activated with rate a, transforming this cell into a virus
producing post-integration infected T-cell T2. The average rates of
change of the different species are given by the following system of
ODEs:
d
dt
TU~lTzdPIC,T:T1(i){dT:TU{
X
i
bT(i,j)
:VI(i):TU
d
dt
MU~lMzdPIC,M:M1(i){dM:MU{
X
i
bM(i,j)
:VI(i):MU
d
dt
T1(i)~bT(i,j)
:VI(i):TU{(dT1zdPIC,TzkT(i,j))
:T1(i)
d
dt
M1(i)~bM(i,j)
:VI(i):MU
{(dM1zdPIC,MzkM(i,j))
:M1(i)
ð3Þ
d
dt
TL(i)~
X
k
p:kT(k,j)T1(k):rk?i{ dLzað Þ:TL(i)
d
dt
T2(i)~
X
k
(1{p):kT(k,j)T1(k):rk?iza:TL(i){dT2
:T2(i)
d
dt
M2(i)~
X
k
kM(k,j)M1(k):rk?i{dM2
:M2(i)
d
dt
VI(i)~NM(i,j):M2(i)zNT(i,j):T2(i){
VI(i):½CLz(CLT(i,j)zbT(i,j))TUz
(CLM(i,j)zbM(i,j))MU
d
dt
VNI~
X
i
½(bNT{NT(i,j))T2(i)z
(bNM{NM(i,j))M2(i){CL:VNI,
where lT and lM are the birth rates of uninfected T-cells and
macrophages, and dT and dM denote their death rate constants.
The parameters kT(k,j) and kM(k,j) are the integration rate
constants of mutant strain k under treatment j. The parameters
dT1 ,dL,dT2 ,dM1 and dM2 are the death rate constants of
T1,TL,T2,M1 and M2 cells, respectively. The free virus (infectious
and non-infectious) gets cleared by the immune system with rate
constant CL. The parameters dPIC,T and dPIC,M refer to the
intracellular degradation of essential components of the pre-
integration complex, e.g., by the host cell proteasome within early
infected T-cells and macrophages, respectively. bNT and bNM
denote the total number of released infectious and non-infectious
virus from late infected T-cells and macrophages of mutant strain
i, and NT(i,j) and NM(i,j) are the rates of release of infective virus
under treatment j. The parameters CLT(i,j) and CLM(i,j) denote
the clearance of mutant virus i through unsuccessful infection of T-
cells and macrophages, respectively [23], and the parameters
bT(i,j) and bM(i,j) denote the successful infection rate constants of
mutant virus i under treatment j for T-cells and macrophages,
respectively. In our model, T-cells can become latently infected TL
with probability p. Latent infected cells can undergo apoptosis
with rate dL and can become activated with rate a. Activation of
latent cells by antigen- or other activating stimuli triggers the
production of viral building blocks via positive feedback loops
[55,56] in the late replication cycle of HIV, which turns the cell
into a virus producing cell T2 that becomes susceptible to HIV-
related cytopathic effects and destruction by the immune system.
The parameter rk?i denotes the probability to mutate from
strain k to strain i and is defined by
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rk?i~m
h(i,k):(1{m)L{h(i,k), ð4Þ
where m denotes the point mutation probability per base and
reverse transcription process (m&2:16:10{5 [42]), h(i,k) denotes
the hamming distance between strain k and strain i, and L is the
total number of different positions that are considered in our
model (here, L~6 point mutations). In total, the model includes
2L different viral strains i that contain point mutations in any
pattern of the modelled L possible mutations. The phenotype of
each mutant strain i is modelled by introducing a selective
disadvantage s(i), which denotes the loss of functionality (e.g., in
the activity of some viral enzyme that is affected by the mutation)
relative to the wildtype, and a strain specific inhibitory activity
g(i,j) of treatment j against the mutant strain i. For example, the
strain specific infection rate i under a certain treatment j is given
by b(i,j)~(1{g(i,j)):(1{s(i)):b(wt,w), where b(wt,w) denotes the
infection rate constant of the wildtype 0wt’ in the absence of drug
w (parameters listed in Table 1). The strain-specific specific
inhibitory activity is calculated via g(i,j)~g(wt,j):res(i,j), where
the efficacy of the drugs against the wildtype g(wt,j) is generally
stated in the corresponding tables and figures (Fig. 2, Fig. 5 and
Table 2) and the resistance of a particular mutant res(i,j) was
either set to 1 (100% susceptible) or 0.01 (99% resistant), if the
particular mutant iconferred resistance to the particular drug j.
All parameter values have been chosen according to previous
studies (see Table 1). The particular viral decay dynamics after
application of distinct drug classes were validated in [23]. The
model (Fig. 1) with above described parameters reproduces an
average frequency of latently infected cells of 26

106 CD4z cells
(reference range: 0:82

106 – 205

106 CD4z cells [2,7,30,31]), a
total of 4:5:106 latently infected cells (reference: 1:4:106 [7]), with
a halflife of 20.6 month (average of [2,57–60]: 21 month) and a
plasma viremia of &1 HIV RNA/mL [61] from the latent
reservoir.
Realization and Implementation of the Model
The overall virus dynamics in our model comprise different viral
strains with copy numbers that can vary over several orders of
magnitude. For this reason we have chosen a hybrid (stochastic-
deterministic) setting for numerical simulation. This approach (i)
takes into account stochastic fluctuations in the slow reaction
processes; and (ii) reduces the computational costs for the
simulation of the fast (deterministic) system dynamics. We used
the direct hybrid method proposed in [25], where we treated
elementary reactions rj as discrete stochastic processes whenever
their propensity function aj or the quantity of at least one of their
reactants was below a threshold of 20. All other reactions were
approximated as continuous deterministic processes. Elementary
reactions rj with propensity functions aj and their respective net
changes nj can be deduced from eqs. (3). For example, the term
bT
:VI:TU denotes the infection reaction of T-cells by infectious
virus. The propensity function of this reaction is aj~bT
:VI:TU.
This reaction changes the species levels as follows: one TU cell and
one VI virus get consumed (the term is once subtracted from each
corresponding ODE), and one T1 cell is produced (the term is
once added to the ODE of T1).
In brief, the hybrid method comprises the following algorithmic
workflow:
(1) Set initial time t~t0 and initial number of molecules X t0ð Þ.
(2) Generate two uniformly distributed pseudo-random variables
j1 and j2 on the open unit interval 0,1ð Þ and determine the
partitioning of reactions into deterministic and stochastic
subsets D and S, respectively. The latter is realized by
comparing the actual propensity and the reactant levels of
every reaction with pre-specified thresholds. If one value is
below the thresholds, a reaction is included in the stochastic
subset S, otherwise it is put in the deterministic subset D.
(3) Set g tjtð Þ~ln j1ð Þ and solve the ODE system for the
deterministic part of the system starting at time t~t
d
dt
X tð Þ~
X
j[D
njaj X tð Þð Þ, ð5Þ
together with
d
dt
g tjtð Þ~
X
j[S
aj X tð Þð Þ, ð6Þ
until time t~s such that g sjtð Þ~0.
(4) Take the integer m satisfying
Xm{1
j~1
aj X tð Þð Þvj2
X
j[S
aj X tð Þð Þ
ƒ
Xm
j~1
aj X tð Þð Þ with j,m [S,
ð7Þ
in order to determine the stochastic reaction rm to be
performed.
(5) Update X sð Þ according to reaction rm, hence set X sð Þ/
X sð Þznm.
(6) Set t/s, and stop the procedure if the final time is reached.
Otherwise go to Step (2).
The above algorithmic scheme requires the use of numerical
integrators that allow to stop integration in step (3) when a
stochastic reaction event is detected at a time t where g sjtð Þ~0.
The utilized integrator is based on numerical differentiation
formulas [62], and uses strategies for event detection and error-
and step size control comparable to ode15s in MATLAB [63]. To
generate the data for Fig. 4, we performed 12000 hybrid
simulations in total. With realization start (t0~0) the effects of
drug treatment were simulated, until t~730 days was reached.
Every numerical calculation was computed with a relative error
tolerance of 1026 and an absolute error tolerance of 1029. Our
simulation code is provided in Source Code S1–S6.
Reproductive Numbers
For the model above (eq. (3)), the reproductive numbers, which
indicate the expected number of offspring in the next generation,
are defined as follows: the reproductive number RV(i,j) of a single
virus of strain i under treatment j is given by
RV(i,j)~
bT(i,j)TU
:kT(i,j) 1{p:
dL
dLza
 
:NT(i,j)
cu(i,j):cT (i,j):dT2
z
bM(i,j)MU
:kM(i,j):NM(i,j)
cu(i,j):cM (i,j):dM2
,
with constants
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cu(i,j)~CLz CLT(i,j)zbT(i,j)½ TUz CLM(i,j)zbM(i,j)½ MU,
cT (i,j)~dTzdPIC,TzkT(i,j),
cM (i,j)~dMzdPIC,MzkM(i,j):
Since infected cells are also pathogens, which can lead to a
rebound of the disease even in the absence of any virus, we also
determined their basic reproductive numbers under a given
treatment j. The basic reproductive numbers RT1 (i,j) and RM1(i,j)
of the infectious stages T1 and M1, associated with the viral strain
i, are given by
RT1 (i,j)~
kT(i,j) 1{p:
dL
dLza
 
:NT(i,j)
cT (i,j):dT2
: bT(i,j)TUzbM(i,j)MU
cu(i,j)
,
RM1(i,j)~
kM(i,j):NM(i,j)
cM (i,j):dM2
: bT(i,j)TUzbM(i,j)MU
cu(i,j)
:
Finally, the reproductive numbers RT2 (i,j),RTL(i,j) and RM2(i,j)
of the infectious stages T2,TL and M2, associated with the viral
strain i, are given by
RT2 (i,j)~
NT(i,j)
dT2
: kT(i,j)TU
:bT(i,j)
cu(i,j):cT (i,j)
z
kM(i,j)MU:bM(i,j)
cu(i,j):cM (i,j)
 
,
RTL(i,j)~
a
dLza
NT(i,j)
dT2
: kT(i,j)TU
:bT(i,j)
cu(i,j):cT (i,j)
z
kM(i,j)MU:bM(i,j)
cu(i,j):cM (i,j)
 
,
RM2(i,j)~
NM(i,j)
dM2
: kT(i,j)TU
:bT(i,j)
cu(i,j):cT (i,j)
z
kM(i,j)MU:bM(i,j)
cu(i,j):cM (i,j)
 
:
Reproductive Capacity
We have previously introduced the reproductive capacity Rcap(j)
[23], which can be interpreted as the expected total number of
infectious offspring that the infection produces in one round of
replication under a certain treatment j, given the current state of the
infection. In this article, we utilize the reproductive capacity in order
to get individual treatment switching times (see eq. (1), main article),
which are displayed in Fig. 3. The reproductive capacity of the
entire quasi-species ensemble under treatment j is defined as the
weighted sum of the basic reproductive numbers of all pathogenic
stages of mutant strain i, i.e., free virus, infected T-cells and infected
macrophages, weighted by the abundance of the corresponding
pathogenic stage [23]:
Rcap(j)~
X
i
½VI(i)RV(i,j)zT1(i)RT1 (i,j)zM1(i)RM1(i,j)z
T2(i)RT2 (i,j)zTL(i)RTL(i,j)zM2(i)RM2(i,j),
where RV(i,j),RT1 (i,j),RM1(i,j),RT2 (i,j) and RM2(i,j) are the
strain-specific reproductive numbers of the different infective
compartments (see previous sections).
Supporting Information
Figure S1 Time and probability of virological failure
depends on pool-size of archived drug-resistant virus. A:
The median time until virological failure, in relation to the
number of fully-resistant archived virus (fully = resistant against
all drugs in the triple-drug combination). B: Probability that
virological failure occurs within two years after initiation of
HAART therapy as a function of the number of fully-resistant
archived virus. 500 stochastic-deterministic runs were performed
for each pool size of the latently infected drug-resistant reservoir.
Parameter values used: (1{g)= 0.75, s= 0.8.
(PDF)
Table S1 Determination of relevant parameter space
for further investigation. We assessed virological failure rates
after one year of triple drug therapy for varying values of efficacy
(1{g(wt,j)) of drug j against the wildtype 0wt’ and selective
disadvantage per mutation s. All other parameters have been
taken from Table 1. A parameter combination (in terms of
(1{g(wt,j)) and s) was considered relevant, if it produced realistic
failure rates after one year of therapy [29]. Confidence ranges are
indicated in brackets and were calculated using Greenwood’s
formula. Each condition has been evaluated by 100 stochastic
deterministic simulations.
(PDF)
Source Code S1 The File ‘HAART.m’ can be used to simulate
the kinetics of HIV after application of conventional HAART
treatment in MATLAB.
(M)
Source Code S2 The File ‘HIVmodel.m’ builds the original
HIV model used throughout the manuscript for use in MATLAB.
(M)
Source Code S3 The File ‘InductionMaintenance.m’ can be
used to simulate the kinetics of HIV after under the proposed
induction-maintenance therapy in MATLAB.
(M)
Source Code S4 The File ‘PatientMonitoring.m’ contains the
MATLAB implementation of routine patient monitoring.
(M)
Source Code S5 The File ‘ReadMeFirst.txt’ Contains a
description of all supplied source code files, contact details,
information on runtime and execution and a copy of the GNU
public license.
(TXT)
Source Code S6 The File ‘SpeciesLevelsIndices.pdf’ contains an
interpretation of the output generated by executing the provided
MATLAB Source Code Files (Source Code S1–S4).
(PDF)
Acknowledgments
The authors would like to thank Prof. Karin Mo¨lling (Head of Virology
Dep., University Zu¨rich, Switzerland) for helpful comments regarding the
manuscript. We are very grateful to the National University of Ireland in
Maynooth for providing the high-performance computing cluster. Special
thanks to Vanush Misha Paturyan for assistance in scheduling jobs on the
computing cluster.
HIV Dynamics during Pro-Active Treatment Switching
PLoS ONE | www.plosone.org 10 March 2011 | Volume 6 | Issue 3 | e18204
Author Contributions
Conceived and designed the experiments: MvK. Performed the experi-
ments: MvK SM. Analyzed the data: MvK SM HS KA WH CS. Wrote
the paper: MvK HS KA WH CS.
References
1. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997)
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral
therapy. Science 278: 1295–1300.
2. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, et al. (1999)
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of
HIV-1, even in patients on effective combination therapy. Nat Med 5: 512–517.
3. Wong JK, Hezareh M, Gu¨nthard HF, Havlir DV, Ignacio CC, et al. (1997)
Recovery of replication-competent HIV despite prolonged suppression of
plasma viremia. Science 278: 1291–1295.
4. Carter CC, Onafuwa-Nuga A, McNamara LA, Riddell J, Bixby D, et al. (2010)
HIV-1 infects multipotent progenitor cells causing cell death and establishing
latent cellular reservoirs. Nat Med 16: 446–451.
5. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, et al. (1995) In vivo
fate of HIV-1-infected T cells: quantitative analysis of the transition to stable
latency. Nat Med 1: 1284–1290.
6. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, et al. (1997) Presence of
an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.
Proc Natl Acad Sci U S A 94: 13193–13197.
7. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. (1997)
Quantification of latent tissue reservoirs and total body viral load in HIV-1
infection. Nature 387: 183–188.
8. Pierson T, McArthur J, Siliciano RF (2000) Reservoirs for HIV-1: mechanisms
for viral persistence in the presence of antiviral immune responses and
antiretroviral therapy. Annu Rev Immunol 18: 665–708.
9. Siliciano JD, Siliciano RF (2004) A long-term latent reservoir for HIV-1:
discovery and clinical implications. J Antimicrob Chemother 54: 6–9.
10. Lambotte O, Chaix ML, Gubler B, Nasreddine N, Wallon C, et al. (2004) The
lymphocyte HIV reservoir in patients on long-term HAART is a memory of
virus evolution. AIDS 18: 1147–1158.
11. Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, et al. (2010) History
of viral suppression on combination antiretroviral therapy as a predictor of
virological failure after a treatment change. HIV Med 11: 469–478.
12. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid
turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature
373: 123–126.
13. Blumberg HM, Leonard MK, Jasmer RM (2005) Update on the treatment of
tuberculosis and latent tuberculosis infection. JAMA 293: 2776–2784.
14. Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A, et al. (2004) Guidelines
on prevention, diagnosis and treatment of infective endocarditis executive
summary; the task force on infective endocarditis of the european society of
cardiology. Eur Heart J 25: 267–276.
15. Zimmerli W, Ochsner PE (2003) Management of infection associated with
prosthetic joints. Infection 31: 99–108.
16. Curlin ME, Iyer S, Mittler JE (2007) Optimal timing and duration of induction
therapy for HIV-1 infection. PLoS Comput Biol 3: e133.
17. Catanzaro LM, Slish JC, DiCenzo R, Morse GD (2004) Drug interactions with
antiretrovirals. Curr HIV/AIDS Rep 1: 89–96.
18. Carr A (2003) Toxicity of antiretroviral therapy and implications for drug
development. Nat Rev Drug Discov 2: 624–634.
19. D’Amato RM, D’Aquila RT, Wein LM (1998) Management of antiretroviral
therapy for HIV infection: modelling when to change therapy. Antivir Ther 3:
147–158.
20. Martinez-Picado J, Negredo E, Ruiz L, Shintani A, Fumaz CR, et al. (2003)
Alternation of antiretroviral drug regimens for HIV infection. A randomized,
controlled trial. Ann Intern Med 139: 81–89.
21. Negredo E, Paredes R, Peraire J, Pedrol E, Coˆte´ H, et al. (2004) Alternation of
antiretroviral drug regimens for HIV infection. efficacy, safety and tolerability at
week 96 of the Swatch study. Antivir Ther 9: 889–893.
22. Sherr L, Lampe F, Norwood S, Leake-Date H, Fisher M, et al. (2007) Successive
switching of antiretroviral therapy is associated with high psychological and
physical burden. Int J STD AIDS 18: 700–704.
23. von Kleist M, Menz S, Huisinga W (2010) Drug-class specific impact of
antivirals on the reproductive capacity of HIV. PLoS Comput Biol 6: e1000720.
24. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for
the use of antiretroviral agents in HIV-1-infected adults and adolescents
Department of Health and Human Services. December 1, 2009. (http://www.
aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf) (accessed 01-Oct-2010).
pp 1–161.
25. Alfonsi A, Cance`s E, Turinici G, Ventura B, Huisinga W (2005) Exact
simulation of hybrid stochastic and deterministic models for biochemical
systems. ESAIM Proc 14: 1–23.
26. Fabbiani M, Giambenedetto SD, Bracciale L, Bacarelli A, Ragazzoni E, et al.
(2009) Pharmacokinetic variability of antiretroviral drugs and correlation with
virological outcome: 2 years of experience in routine clinical practice.
J Antimicrob Chemother 64: 109–117.
27. Clavel F, Hance AJ (2004) HIV drug resistance. N Engl J Med 350: 1023–1035.
28. Clavel F (2009) HIV resistance to raltegravir. Eur J Med Res 14(Suppl 3): 47–54.
29. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, et al. (2008)
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med
358: 2095–2106.
30. Blankson JN, Finzi D, Pierson TC, Sabundayo BP, Chadwick K, et al. (2000)
Biphasic decay of latently infected CD4+ T cells in acute human immunode-
ficiency virus type 1 infection. J Infect Dis 182: 1636–1642.
31. Fondere JM, Planas JF, Huguet MF, Baillat V, Bolos F, et al. (2004)
Enumeration of latently infected CD4+ T cells from HIV-1-infected patients
using an HIV-1 antigen ELISPOT assay. J Clin Virol 29: 33–38.
32. Richman DD (2000) Principles of HIV resistance testing and overview of assay
performance characteristics. Antivir Ther 5: 27–31.
33. Eriksson N, Pachter L, Mitsuya Y, Rhee SY, Wang C, et al. (2008) Viral
population estimation using pyrosequencing. PLoS Comput Biol 4: e1000074.
34. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, et al. (1999)
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of
compensatory mutations during suboptimal therapy. AIDS 13: 2349–2359.
35. Arora P, Dixit NM (2009) Timing the emergence of resistance to anti-HIV drugs
with large genetic barriers. PLoS Comput Biol 5: e1000305.
36. Markowitz M, Louie M, Hurley A, Sun E, Mascio MD, et al. (2003) A novel
antiviral intervention results in more accurate assessment of human immuno-
deficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 77:
5037–5038.
37. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1
dynamics in vivo: virion clearance rate, infected cell life-span, and viral
generation time. Science 271: 1582–1586.
38. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, et al. (1997) Decay
characteristics of HIV-1-infected compartments during combination therapy.
Nature 387: 188–191.
39. Ji H, Masse´ N, Tyler S, Liang B, Li Y, et al. (2010) HIV drug resistance
surveillance using pooled pyrosequencing. PLoS One 5: e9263.
40. Archer J, Braverman MS, Taillon BE, Desany B, James I, et al. (2009) Detection
of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using
HIV-1 with ultra-deep pyrosequencing. AIDS 23: 1209–1218.
41. Ribeiro RM, Bonhoeffer S, Nowak MA (1998) The frequency of resistant
mutant virus before antiviral therapy. AIDS 12: 461–465.
42. Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human
immunodeficiency virus type 1 than that predicted from the fidelity of purified
reverse transcriptase. J Virol 69: 5087–5094.
43. Martinez-Picado J, Martı´nez MA (2008) HIV-1 reverse transcriptase inhibitor
resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res
134: 104–123.
44. Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S (2010) Evolutionary
dynamics of complex networks of HIV drug-resistant strains: the case of San
Francisco. Science 327: 697–701.
45. Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard JP, et al. (2006) HIV-1
resistant strains acquired at the time of primary infection massively fuel the
cellular reservoir and persist for lengthy periods of time. AIDS 20: 159–170.
46. Bartlett JA (2002) Addressing the challenges of adherence. J Acquir Immune
Defic Syndr 29(Suppl 1): S2–10.
47. Murray JM, Emery S, Kelleher AD, Law M, Chen J, et al. (2007) Antiretroviral
therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV,
significantly reducing the second phase. AIDS 21: 2315–2321.
48. DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, et al. (2006) Antiviral
activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor
gs-9137 (jtk-303) in treatment-naive and treatment-experienced patients.
J Acquir Immune Defic Syndr 43: 1–5.
49. Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF (2008) Decay
dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc
Natl Acad Sci U S A 105: 4832–4837.
50. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JVR, et al. (2009)
Safety and efficacy of raltegravir-based versus efavirenz-based combination
therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-
blind randomised controlled trial. Lancet 374: 796–806.
51. Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, et al. (2010)
Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected
patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
J Acquir Immune Defic Syndr 55: 39–48.
52. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, et al. (1999) Rapid
production and clearance of HIV-1 and hepatitis C virus assessed by large
volume plasma apheresis. Lancet 354: 1782–1785.
53. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010)
Preexposure chemoprophylaxis for HIV prevention in men who have sex with
men. N Engl J Med 363: 2587–2599.
HIV Dynamics during Pro-Active Treatment Switching
PLoS ONE | www.plosone.org 11 March 2011 | Volume 6 | Issue 3 | e18204
54. Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, et al. (2010) Reuse of
nevirapine in exposed HIV-infected children after protease inhibitor-based viral
suppression: a randomized controlled trial. JAMA 304: 1082–1090.
55. Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV (2005)
Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 tat
fluctuations drive phenotypic diversity. Cell 122: 169–182.
56. Lassen KG, Ramyar KX, Bailey JR, Zhou Y, Siliciano RF (2006) Nuclear
retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog
2: e68.
57. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, et al. (1999)
Quantifying residual HIV-1 replication in patients receiving combination
antiretroviral therapy. N Engl J Med 340: 1605–1613.
58. Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, et al. (2007) Decay
of the HIV reservoir in patients receiving antiretroviral therapy for extended
periods: implications for eradication of virus. J Infect Dis 195: 1762–1764.
59. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, et al. (2003) Long-term
follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting
CD4+ T cells. Nat Med 9: 727–728.
60. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, et al. (2000) The decay
of the latent reservoir of replication-competent HIV-1 is inversely correlated
with the extent of residual viral replication during prolonged anti-retroviral
therapy. Nat Med 6: 82–85.
61. Coffin J, Maldarelli F, Palmer S, Weigand A, Brun S, et al. (2006) Long-term
persistance of low-level HIV-1 in patients on suppressive antiretroviral therapy.
Abstract 169 13th Conference on Retroviruses and Opportunistic Infections; 5–
8 February 2006; Denver, Colorado, United States Available at http://
wwwretroconferenceorg/2006/Abstracts/28061htm.
62. Klopfenstein R (1971) Numerical differentiation formulas for stiff systems of
ordinary differential equations. RCA Review 32: 447–462.
63. Shampine L, Reichelt M (1997) The Matlab ODE Suite. SIAM Journal on
Scientific Computing 18: 1–22.
64. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral
dynamics in human immunodeficiency virus type 1 infection. Nature 373:
117–122.
65. Sedaghat AR, Siliciano RF, Wilke CO (2009) Constraints on the dominant
mechanism for HIV viral dynamics in patients on raltegravir. Antivir Ther 14:
263–271.
66. Callaway DS, Perelson AS (2002) HIV-1 infection and low steady state viral
loads. Bull Math Biol 64: 29–64.
67. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, et al. (2008) Dynamics of
total, linear nonintegrated, and integrated HIV-1DNA in vivo and in vitro.
J Infect Dis 197: 411–419.
68. Zhou Y, Zhang H, Siliciano JD, Siliciano RF (2005) Kinetics of human
immunodeficiency virus type 1 decay following entry into resting CD4+ T cells.
J Virol 79: 2199–2210.
69. Pierson TC, Zhou Y, Kieffer TL, Ruff CT, Buck C, et al. (2002) Molecular
characterization of preintegration latency in human immunodeficiency virus
type 1 infection. J Virol 76: 8518–8531.
HIV Dynamics during Pro-Active Treatment Switching
PLoS ONE | www.plosone.org 12 March 2011 | Volume 6 | Issue 3 | e18204
